A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction.

Trial Profile

A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Sponsors Osiris Therapeutics
  • Most Recent Events

    • 19 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 02 Jul 2012 Interim 1-year results published in an Osiris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top